A detailed history of Efg Asset Management (North America) Corp. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 20,615 shares of ALNY stock, worth $5.06 Million. This represents 0.97% of its overall portfolio holdings.

Number of Shares
20,615
Previous 18,584 10.93%
Holding current value
$5.06 Million
Previous $4.52 Million 25.58%
% of portfolio
0.97%
Previous 0.8%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$233.81 - $287.01 $474,868 - $582,917
2,031 Added 10.93%
20,615 $5.67 Million
Q2 2024

Jul 25, 2024

SELL
$143.31 - $247.0 $195,188 - $336,414
-1,362 Reduced 6.83%
18,584 $4.52 Million
Q1 2024

May 13, 2024

SELL
$146.51 - $198.2 $547,947 - $741,268
-3,740 Reduced 15.79%
19,946 $2.98 Million
Q4 2023

Feb 08, 2024

SELL
$151.41 - $196.57 $630,622 - $818,714
-4,165 Reduced 14.95%
23,686 $4.53 Million
Q3 2023

Nov 02, 2023

SELL
$170.77 - $211.65 $51,231 - $63,495
-300 Reduced 1.07%
27,851 $4.93 Million
Q2 2023

Jul 28, 2023

BUY
$185.01 - $212.05 $76,964 - $88,212
416 Added 1.5%
28,151 $5.35 Million
Q1 2023

Apr 27, 2023

SELL
$182.66 - $235.53 $155,078 - $199,964
-849 Reduced 2.97%
27,735 $5.56 Million
Q4 2022

Feb 03, 2023

SELL
$185.53 - $241.31 $31,540 - $41,022
-170 Reduced 0.59%
28,584 $6.79 Million
Q3 2022

Oct 28, 2022

BUY
$138.54 - $232.0 $260,455 - $436,160
1,880 Added 7.0%
28,754 $5.75 Million
Q2 2022

Aug 04, 2022

SELL
$120.42 - $169.29 $1.48 Million - $2.09 Million
-12,321 Reduced 31.44%
26,874 $3.92 Million
Q1 2022

Apr 26, 2022

BUY
$127.18 - $173.91 $4.98 Million - $6.82 Million
39,195 New
39,195 $6.4 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.